Paratek Announces Pricing of Public Offering of Common Stock
January 18, 2018 09:41 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Announces Public Offering of Common Stock
January 17, 2018 16:06 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Provides Update on Pipeline Progress
January 03, 2018 07:00 ET
|
Paratek Pharmaceuticals
Rolling NDA submission underway for omadacycline in pneumonia and skin infectionsOmadacycline Phase 2 program underway for the treatment of urinary tract infections$5 million milestone payment earned...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 01, 2017 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018
November 08, 2017 07:00 ET
|
Paratek Pharmaceuticals
Granted QIDP designation for uncomplicated Urinary Tract Infections (uUTI) by the FDA Highlighted prelaunch activities during Investor Day presentations in October BOSTON, Nov. 08, 2017 (GLOBE...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 01, 2017 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017
October 24, 2017 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria
October 06, 2017 08:01 ET
|
Paratek Pharmaceuticals
SAN DIEGO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- New microbiology data from Paratek Pharmaceuticals (Nasdaq:PRTK) show that its well-tolerated, once-daily, oral and IV, broad-spectrum investigational...
Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions
October 06, 2017 08:00 ET
|
Paratek Pharmaceuticals
- No dosing adjustment anticipated in these special populations SAN DIEGO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals (Nasdaq:PRTK) announced the results of three sub-analyses from...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 02, 2017 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...